Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 9/2011

01-09-2011 | Short Communication

Neutralization of Neisseria meningitidis outer membrane vesicles

Authors: András Vida, Annet Troelstra, Péter Antal-Szalmás, Toon J. P. van Bommel, André F. M. Verheul, Jan Verhoef, Kok P. M. van Kessel, Jos A. G. van Strijp

Published in: Inflammation Research | Issue 9/2011

Login to get access

Abstract

Introduction

We aimed to determine the neutralization of Neisseria meningitidis outer membrane vesicles (blebs) by humoral and cellular elements of whole blood.

Methods

The interaction of FITC-labeled blebs with monocytes was studied by spectrofluorometry. Blebs are able to induce an oxidative burst in neutrophils, and we evaluated the inhibitory effect of plasma on this process.

Results

Human plasma reduced the priming activity of blebs containing 1–3 ng/ml lipopolysaccharide (LPS) by 50–60% and bactericidal permeability increasing protein (BPI) reduced priming to background levels. A complete neutralization of LPS and blebs by plasma and BPI was measured using the limulus amebocyte lysate (LAL) assay. Furthermore, only 3% of blebs were cell-associated, while the remainder were in the supernatant.

Conclusions

Plasma and BPI are able to neutralize blebs, with phagocytosis playing only a minor role. As such, we conclude that blebs do not behave like particles but more like free LPS.
Literature
1.
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine Suppl. 2009;2:B51–63.CrossRef
2.
Namork E, Brandtzaeg P. Fatal meningococcal septicaemia with “blebbing” meningococcus. Lancet. 2002;360:1741.PubMedCrossRef
3.
Ingalls RR, Lien E, Golenbock DT. Differential roles of TLR2 and TLR4 in the host response to gram-negative bacteria: Lessons from a lipopolysaccharide-deficient mutant of Neisseria meningitidis. J Endotoxin Res. 2000;6:411–5.PubMed
4.
Bjerre A, Brusletto B, Rosenqvist E, Namork E, Kierulf P, Ovstebo R, et al. Cellular activating properties and morphology of membrane-bound and purified meningococcal lipopolysaccharide. J Endotoxin Res. 2000;6:437–45.PubMed
5.
Post DM, Zhang D, Eastvold JS, Teghanemt A, Gibson BW, Weiss JP. Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J Biol Chem. 2005;280:38383–94.PubMedCrossRef
6.
Gioannini TL, Weiss JP. Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res. 2007;39:249–60.PubMedCrossRef
7.
Sprong T, Moller AS, Bjerre A, Wedege E, Kierulf P, van der Meer JW, et al. Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide. Infect Immun. 2004;72:3344–9.PubMedCrossRef
8.
Zughaier SM, Tzeng YL, Zimmer SM, Datta A, Carlson RW, Stephens DS. Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun. 2004;72:371–80.PubMedCrossRef
9.
Schultz H, Hume J, de Zhang S, Gioannini TL, Weiss JP. A novel role for the bactericidal/permeability increasing protein in interactions of gram-negative bacterial outer membrane blebs with dendritic cells. J Immunol. 2007;179:2477–84.PubMed
10.
Verheul AF, Boons GJ, Van der Marel GA, Van Boom JH, Jennings HJ, Snippe H, et al. Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect Immun. 1991;59:3566–73.PubMed
11.
Troelstra A, Antal-Szalmas P, de Graaf-Miltenburg LA, Weersink AJ, Verhoef J, Van Kessel KP, et al. Saturable CD14-dependent binding of fluorescein-labeled lipopolysaccharide to human monocytes. Infect Immun. 1997;65:2272–7.PubMed
12.
Van Strijp JA, Van Kessel KP, van der Tol ME, Verhoef J. Complement-mediated phagocytosis of herpes simplex virus by granulocytes. Binding or ingestion. J Clin Invest. 1989;84:107–12.PubMedCrossRef
13.
Poolman JT. Development of a meningococcal vaccine. Infect Agents Dis. 1995;4:13–28.PubMed
14.
Troelstra A, Giepmans BN, Van Kessel KP, Lichenstein HS, Verhoef J, Van Strijp JA. Dual effects of soluble CD14 on LPS priming of neutrophils. J Leukoc Biol. 1997;61:173–8.PubMed
15.
Iovine N, Eastvold J, Elsbach P, Weiss P, Gioannini TL. The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes. J Biol Chem. 2002;277:7970–8.PubMedCrossRef
16.
Novitsky TJ, Roslansky PF. Quantification of endotoxin inhibition in serum and plasma using a turbidimetric LAL assay. Prog Clin Biol Res. 1985;189:181–96.PubMed
17.
Wurfel MM, Wright SD. Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins. Prog Clin Biol Res. 1995;392:287–95.PubMed
Metadata
Title
Neutralization of Neisseria meningitidis outer membrane vesicles
Authors
András Vida
Annet Troelstra
Péter Antal-Szalmás
Toon J. P. van Bommel
André F. M. Verheul
Jan Verhoef
Kok P. M. van Kessel
Jos A. G. van Strijp
Publication date
01-09-2011
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 9/2011
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-011-0344-3

Other articles of this Issue 9/2011

Inflammation Research 9/2011 Go to the issue

Original Research Paper

Methyl-1-hydroxy-2-naphthoate, a novel naphthol derivative, inhibits lipopolysaccharide-induced inflammatory response in macrophages via suppression of NF-κB, JNK and p38 MAPK pathways

Original Research Paper

BAFF and APRIL induce inflammatory activation of THP-1 cells through interaction with their conventional receptors and activation of MAPK and NF-κB

Original Research Paper

Folic acid inhibits lipopolysaccharide-induced inflammatory response in RAW264.7 macrophages by suppressing MAPKs and NF-κB activation

Original Research Paper

Expression of IgA class switching gene in tonsillar mononuclear cells in patients with IgA nephropathy

Original Research Paper

Inhibition of inflammatory mediators and related signaling pathways by macrophage-stimulating protein in rheumatoid arthritis synovial fibroblasts

Original Research Paper

Role of heme oxygenase-1 in inflammatory response induced by mechanical stretch in synovial cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits